Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 435 across all filing types
Latest filing 2024-05-27 Call Transcript
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is titled 'Q4 FY24 Earnings Conference Call Transcript' and includes detailed discussions of quarterly and full fiscal year financial results, including revenue, EBITDA, EPS, and business segment performance. It contains a full transcript of the earnings call with management commentary and Q&A. The document references the quarter ended March 31, 2024, and discusses financial highlights and outlook. It is not a brief announcement or a report publication notice but a full transcript of the earnings call. Therefore, it fits the definition of a Call Transcript (CT).
2024-05-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about the recording of a conference call related to the company's audited financial results for the quarter and financial year ended March 31, 2024. It mentions that the audio recording has been uploaded on the company's website and that the transcript will be shared and uploaded in due course. The document itself does not contain the transcript or detailed financial data but is an announcement about the availability of the conference call recording and future transcript. The document length is 2140 characters, which is relatively short and fits the pattern of an announcement rather than the full transcript. According to the rules, announcements about conference calls or transcripts are classified as Regulatory Filings (RNS) unless the full transcript is provided. Therefore, this document should be classified as Regulatory Filings (RNS).
2024-05-21 English
Change in Management
Board/Management Information Classification · 100% confidence The document is an official communication from Windlas Biotech Limited to stock exchanges (BSE and NSE) regarding the re-appointment of an Executive Director, Mr. Pawan Kumar Sharma. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in the company's board or management. The content includes details about the director's re-appointment, brief profile, and regulatory compliance information. There are no financial statements or performance data, nor is this a report or announcement of financial results. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-05-20 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Windlas Biotech Limited Investor Presentation – May 2024' and includes comprehensive financial data for the quarter and fiscal year ended March 31, 2024. It contains management messages, financial performance highlights, quarterly and annual financial data, and strategic outlook. The document is about 15,000 characters long, indicating it is a full presentation rather than a brief announcement. The content focuses on financial results, business segments, and outlook, which aligns with the characteristics of an Investor Presentation. There is no indication that this is an earnings release (which would be shorter and more summary), nor is it a full annual report or interim report with full financial statements. It is not a regulatory filing or announcement of a report publication. Therefore, the most appropriate classification is Investor Presentation (IP).
2024-05-20 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated May 20, 2024, announcing the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2024. It contains detailed financial highlights including revenue, EBITDA, PAT, EPS, liquidity, and segment performance for FY24 and Q4FY24. The document includes management commentary on the results and business outlook. It is not the full annual report but a press release summarizing key financial results. The document length is 11,109 characters, which is substantial but typical for a press release. There is no indication that this is the full Annual Report (10-K) or a detailed Management Discussion & Analysis (MDA) report. It is also not a certification, proxy, or regulatory filing. Therefore, the document fits best as an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only. FY 2024
2024-05-20 English
Outcome of Board Meeting
Regulatory Filings
2024-05-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.